

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet

1

①

1

Attorney Docket Number

MEMORY-28

Application Number

10/622,833

Filing Date

July 21, 2003

First Named Inventor

Richard A. SCHUMACHER et al

Group Art Unit

Unassigned	1626
------------	------

Examiner Name

Unassigned

Attorney Docket Number

MEMORY-28

[illegible][illegible]

**Examiner
Signature**

Date Considered

12/8/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

* already considered on 9/2/05 LOS Rb

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

U.S. PATENT DOCUMENTS

Examine Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
Rb		5,622,977		Warrellow et al.	04/22/1997	
Rb		5,633,257		Warrellow et al.	05/27/1997	
Rb		5,679,696		Fenton et al.	10/21/1997	
Rb		5,693,659		Head et al.	12/02/1997	
Rb		5,698,711		Palfreyman	12/16/1997	
Rb		5,710,160		Guay et al.	01/20/1998	
Rb		5,710,170		Guay et al.	01/20/1998	
Rb		5,712,298		Amschler	01/27/1998	
Rb		5,723,460		Warrellow et al.	03/03/1998	
Rb		5,728,712		Montana et al.	03/17/1998	
Rb		5,739,144		Warrellow et al.	04/14/1998	
Rb		5,776,958		Warrellow et al.	07/07/1998	
Rb		5,780,477		Head et al.	07/14/1998	
Rb		5,780,478		Alexander et al.	07/14/1998	
Rb		5,786,354		Warrellow et al.	07/28/1998	
Rb		5,798,373		Warrellow et al.	08/25/1998	
Rb		5,840,724		Fenton et al.	11/24/1998	
Rb		5,849,770		Head et al.	12/15/1998	
Rb		5,859,034		Warrellow et al.	01/12/1999	
Rb		5,891,896		Warrellow et al.	04/06/1999	
Rb		5,866,593		Warrellow et al.	02/02/1999	
Rb		5,919,937		Lynch et al.	07/06/1999	
Rb		5,935,978		Fenton et al.	08/10/1999	
Rb		5,962,483		Warrellow et al.	10/05/1999	
Rb		5,962,492		Warrellow et al.	10/05/1999	
Rb		6,077,854		Warrellow et al.	06/20/2000	
Rb		5,814,651		Duplantier et al	09/29/1998	
Rb		6,255,326		Ashton et al.	07/03/2001	
Rb		6,096,768		Ashton et al.	08/01/2000	
Rb		6,162,830		Connor et al.	12/19/2000	
Rb		6,180,650		Frenette et al.	01/30/2001	
Rb		6,200,993		Cote et al.	03/13/2001	

Examiner
Signature

Kelvin J. Anderson

Date
Considered

10/18/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

U.S. PATENT DOCUMENTS

Examine r Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
RL		6,204,275		Friesen et al.	03/20/2001	
RL		6,245,774		Warrellow et al.	06/12/2001	
RL		6,297,264		Head et al.	10/02/2001	
RL	1	5,880,135			3/9/1999	
RL	2	6,262,040			7/17/2001	
RL	3	6,040,329			3/21/2000	

FOREIGN PATENT DOCUMENTS

Examine r Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
RL		FR	2729142	A1	Nadler et al.	07/12/1996		
RL		EP	1116711	A2	Chassot et al	07/18/2001		
RL		EP	0994100	A1	Shinji et al.	04/19/2000		
RL		WIPO	00/71129	A1	Hunt et al	11/30/2000		
RL		WIPO	94/27971	A1	Nadler et al.	12/08/1994		
RL		WIPO	93/25517			12/23/1993		
RL		WIPO	94/14742			07/07/1994		
RL		WIPO	98/58901			12/30/1998		
RL		JP	11-189577			07/13/1999		
RL		WIPO	96/23754			08/08/1996		
RL		WIPO	99/33806		John et al.	07/1999		
RL		WIPO	96/36620		Giulio et al	11/1996		
RL		WO	00/64874			11/2000		
RL		WO	01/70738			9/27/01		
RL		WO	94/02465			2/3/94		
RL		WO	95/01338			1/12/95		
RL		JP	2001 11047			1/16/2001		
RL		WO	02 059110		PCT	8/1/2002		
RL		WO	97 00868		PCT	1/9/1997		1
RL		WO	98 09961		PCT	3/12/1998		2
RL		WO	97 49702		PCT	12/31/1997		3
RL		WO	00 69841		PCT	11/23/2000		

Examiner
Signature

Rebecca Anderson

Date
Considered

12/8/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

already considered on 9/16/05 IDS RL

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RB		HEILMAN et al, "Synthesis and Antiinflammatory Evaluation of Substituted Isophthalonitriles, Trimesonitriles, Benzonitriles, and Terephthalonitriles", Journal of Medicinal Chemistry, 1978, Vol. 21, No. 9, pp. 906-913, XP-002226236	
RB		WATANABE et al, "Structure-Activity Relationship and Rational Design of 3,4-Dephosphatase Derivatives as Protein Tyrosine Phosphatase Inhibitors", Pergamon Tetrahedron, 2000, Vol. 56, pp. 741-752	
RB		INOUE et al, "Steric Tuning in Chiral Ligand Mediated Enantioselective Alkylation of Imines", Tetrahedron: Asymmetry, 1993, Vol. 4, No. 7, pp. 1603-1606, XP002226237	
RB		THOMAS C. MCKENZIE et al., "The Gomberg-Bachmann Reaction of Purines", J. Heterocyclic Chem., May-Jun 1987, pp. 859-861, Vol. 24	
RB		VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," J. Am. Chem. Soc., 1989, pp. 8502-8504, Vol. 111	
RB		VASU NAIR et al., "Synthesis Of Congeners Of Adenosine Resistant To Deamination By Adenosine Deaminase," J. Chem. Soc Comm., 1989, pp. 878-879	
RB		JAMES L. KELLEY et al., "Synthesis and Structure- Activity Relationships of 2-Substituted-6-(dimethylamino)- 9-(4-methylbenzyl)-9H-purines with Antirhinovirus Activity," J. Med. Chem., 1989, pp. 218-224, Vol. 32	
RB		JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," Eur. J. Med. Chem., 1990, pp. 131-135, Vol. 25	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Rt		ROGER J. SCHILLING et al., "A High-Throughput Assay For Cyclic Nucleotide Phosphodiesterases," <u>Analytical Biochemistry</u> , 1994, pp.154-158, Vol. 215	
Rb		DONALD V. DANIELS et al., "A Semiautomated Method for the Assay of Cyclic Adenosine 5'-Monophosphate Phosphodiesterase," <u>Analytical Biochemistry</u> , 1996, pp. 367-369, Vol. 236	
Rb		JEAN-JACQUES BOURGUIGNON et al., "9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors," <u>J. Med. Chem.</u> , 1997, pp. 1768-1770, Vol. 40	
Rb		JAMES L. KELLEY et al., "6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," <u>J. Med. Chem.</u> , 1997, pp. 3207-3216, Vol. 40	
Rb		HIROYUKI SAWANISHI et al., "Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines," <u>J. Med. Chem.</u> , 1997, pp. 3248-3253, Vol. 40	
Rb		J.E. SOUNNES et al., "Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases," <u>Cell Signal</u> , 1997, pp. 227-236. Vol. 9, No. 3-4	
Rb		MARY ELIZABETH BACH et al., "Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long term potentiation <i>in vitro</i> and are attenuated by drugs that enhance the cAMP signaling pathway," <u>Proc. Natl. Acad. Sci. USA</u> , April 1999, pp.5280-5285, Vol. 96	
Rb		ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," <u>The Journal Of Pharmacology And Experimental Therapeutics</u> , 2000, pp. 647-653, Vol 292, No.2	
Rb		Anil S. GURAM et al., "A Simple Catalytic Method for the conversion of Aryl Bromides to Arylamines," <u>Angew. Chem. Int. Ed. Engl.</u> , 1995, Vol. 34, No. 12, pp. 1348-1350.	
Rb		Michael S. DRIVER et al., "A Second-Generation Catalyst for the Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdCl ₂ ," <u>J. Am. Chem. Soc.</u> , 1996, Vol. 118, pp. 7217-7218.	
Rb		Takashi EGAWA et al., "Rolipram and its Optical Isomers, Phosphodiesterase 4 Inhibitors, Attenuated the Scopolamine-Induced Impairments of Learning and Memory in Rats," <u>J. Pharmacol.</u> , Vol. 75, 275-281(1997).	
Rb		Peng WANG et al., "Expression, Purification, and Characterization of Human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D," <u>Biochem. And Biophys. Research Comm.</u> , Vol. 234, 320-324 (1997).	

Examiner Signature

Kelvin Jones

Date

Considered

12/8/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RA		JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <i>Eur. J. Med. Chem.</i> , 1990, pp. 131-135, Vol. 25	
RA		Domine M. T. CHAN et al., "New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate," <i>Tetrahedron Letters</i> , Vol. 39, 2933-2936 (1998).	
RA		Mark BARAD et al., "Rolipram, a Type IV-Specific Phosphodiesterase Inhibitor Facilitates the Establishment of Long-lasting Long-term Potentiation and Improves Memory," <i>Proc. Natl. Acad. Sci.</i> , Vol. 95, pp. 15020-15025 (December 1998).	
RA		Miles D. HOUSLAY et al., "The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions," <i>Advances in Pharmacology</i> , Vol. 44, pp. 225-342, 1998.	
RA		John HARTWIG et al., "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand," <i>J. Org. Chem.</i> , 1999, Vol. 64, pp. 5575-5580.	
RA		Han-Ting ZHANG et al., "Inhibition of Cyclic AMP Phosphodiesterase (PDE4) Reverses Memory Deficits Associated with NDMA Receptor Antagonism," <i>Neuropsychopharmacology</i> , 2000, Vol. 23, pp. 198-204.	
RA		Han-Ting ZHANG et al., "Effects of Rolipram on Scopolamine-induced Impairment of Working and Reference Memory in the Radial-arm Maze tests in Rats," <i>Psychopharmacology (Berl)</i> 2000 June;150(3):pp. 311-6.	
RA		T.W. Greene et al., <i>Protective Groups in Organic Synthesis</i> , 3 rd Edition, Chapter 3, "Protection for Phenols and Catechols," pp. 246-292, John Wiley & Sons, 1999	
/RA/		International Search Report from PCT Application No. PCT/US02/01508, dated January 16, 2003	

Examiner
Signature

Kathleen Anderson

Date
Considered

12/8/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.